Facebook
Twitter
LinkedIn
Forward
Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists - English (2024)
COMPLIMENTARY CME LIVE VIRTUAL COURSE!
Join the AUA for Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists - English (2024), featuring a dynamic live webinar tailored specifically for Urologists and presented in English. This FREE live virtual course will showcase an expert multidisciplinary panel ready to dive into an engaging discussion on the latest breakthroughs and strategies in NMIBC management on Thursday, December 19, 2024, 7-8:30 p.m. Eastern Time. Don’t miss this chance to elevate your expertise in this critical field. Register today!
Expert Faculty:
- Moderator: John L. Gore, MD, MS
- Panelists: Peter Black, MD; Pauline Filippou, MD; Vadim Koshkin, MD
Acknowledgements
Support provided by independent educational grants from:
- ImmunityBio, Inc.
- Merck & Co., Inc.
- UroGen Pharma, Inc.
Target Audience
- Urologists
Learning Objectives
After participating in this CME activity, participants will be able to:
- Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions.
- Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.
- Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC.
- Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies.
- Properly manage adverse events associated with NMIBC treatment.
Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists - English (2024)
Thursday, December 19, 2024
7-8:30 p.m. ET
Agenda
Welcome and Introductions
Pre-test
Segment 1: Assessing Risk Stratification of Love, Intermediate, and High-Risk NMIBC
Segment 2: NMIBC Diagnostic Techniques
Segment 3:Personalized Management of NMIBC - Tailoring Treatment Strategies Based on Patient Characteristics and Tumor Biology
Segment 4: New and Emerging NMIBC Therapies
Segment 5: Proper Management of NMIBC Treatment Adverse Events
Post-test
Questions and Answers
Wrap-up
FACULTY DISCLOSURES
| Name | Company Name | Relationship Type | End Date |
| Black, Peter Colin | Janssen | Consultant or Advisor | Current |
| Astellas | Consultant or Advisor | Current | |
| AbbVie | Consultant or Advisor | Current | |
| Roche/Genentech | Consultant or Advisor | 12/31/2022 | |
| Merck | Consultant or Advisor | Current | |
| Pfizer | Meeting Participant or Lecturer | Current | |
| Prokarium | Consultant or Advisor | Current | |
| Ferring | Consultant or Advisor | Current | |
| UroGen | Consultant or Advisor | 12/31/2023 | |
| Verity Pharmaceuticals | Consultant or Advisor | Current | |
| NanOlogy | Consultant or Advisor | Current | |
| AstraZeneca | Consultant or Advisor | Current | |
| Protara | Consultant or Advisor | 12/31/2022 | |
| TerSera | Meeting Participant or Lecturer | Current | |
| Sumitomo | Consultant or Advisor | Current | |
| CG Oncology | Consultant or Advisor | Current | |
| Engene | Consultant or Advisor | Current | |
| Filippou, Pauline | No relevant financial relationships to disclose | ||
| Gore, John Lawrence | Seagen, Inc. | Scientific Study or Trial | 01/01/2024 |
| Astellas | Consultant or Advisor | Current | |
| Koshkin, Vadim | Astellas | Consultant or Advisor | Current |
| Janssen | Consultant or Advisor | Current | |
| Nektar | Scientific Study or Trial | Current | |
| Eli Lilly | Scientific Study or Trial | Current | |
| Merck | Scientific Study or Trial | Current | |
EDUCATION COUNCIL DISCLOSURES
Education Council Disclosures_June 2024.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures_June 2024.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification relevant financial relationships that result in of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
Registration for Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists - English (2024) is complimentary, however should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contacting education@auanet.org.
To join the live virtual course:
- Click on the TAKE COURSE button.
- Click “Live Virtual Course” in the Course Progress pane.
- Click the link to register in advance.
- After registering, you will receive a confirmation email containing information about joining the live virtual course.
Attendee Information & Policies
AUA Anti-Harassment Policy
AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.
Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly.
The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).
Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.
Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.